Vimarsana
Biggest News Aggregation in the World

Page 4 - Planned Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Planned Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Planned Phase Today - Breaking & Trending Today

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results - Vimarsana News

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results - Vimarsana News

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...

Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27% - Vimarsana News

Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%

09.02.2022 - -FC2 Prescription Business Entering 6th Year of Growth - -FDA Approves Company’s ENTADFI, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway- -Company Enters into Clinical Trial ...

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences - Vimarsana News

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences - Vimarsana News

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...